Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions

被引:0
|
作者
Kang, Zhen [1 ,6 ]
Margolis, Daniel J. [2 ]
Tian, Ye [3 ]
Li, Qiubai [4 ]
Wang, Shaogang [5 ]
Wang, Liang [6 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China
[2] New York Presbyterian, Weill Cornell Med, Dept Radiol, New York, NY USA
[3] Capital Med Univ, Affiliated Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China
[4] Univ Hosp Cleveland Med Ctr, Dept Radiol, Cleveland, OH USA
[5] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China
[6] Capital Med Univ, Beijing Friendship Hosp, Dept Radiol, Beijing, Peoples R China
关键词
Prostate cancer; Clinically significant prostate cancer; PI-RADS; 3; Coefficient of variation; Apparent diffusion coefficient; APPARENT DIFFUSION-COEFFICIENT; DENSITY; GRADE; MRI;
D O I
10.1016/j.urolonc.2024.06.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To explore the feasibility and efficacy of clinical-imaging metrics in the diagnosis of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) in prostate imaging-reporting and data system (PI-RADS) category 3 lesions. Methods: A retrospective analysis was conducted on lesions diagnosed as PI-RADS 3. They were categorized into benign, non-csPCa and csPCa groups. Apparent diffusion coefficient (ADC), T2-weighted imaging signal intensity (T2WISI), coefficient of variation of ADC and T2WISI, prostate-specific antigen density (PSAD), ADC density (ADCD), prostate-specific antigen lesion volume density (PSAVD) and ADC lesion volume density (ADCVD) were measured and calculated. Univariate and multivariate analyses were used to identify risk factors associated with PCa and csPCa. Receiver operating characteristic curve (ROC) and decision curves were utilized to assess the efficacy and net benefit of independent risk factors. Results: Among 202 patients, 133 had benign prostate disease, 25 non-csPCa and 44 csPCa. Age, PSA and lesion location showed no significant differences (P> 0.05) among the groups. T2WISI and coefficient of variation of ADC (ADCcv) were independent risk factors for PCa in PI-RADS 3 lesions, yielding an area under the curve (AUC) of 0.68. ADC was an independent risk factor for csPCa in PI-RADS 3 lesions, yielding an AUC of 0.65. Decision curve analysis showed net benefit for patients at certain probability thresholds. Conclusions: T2WISI and ADCcv, along with ADC, respectively showed considerable promise in enhancing the diagnosis of PCa and csPCa in PI-RADS 3lesions.
引用
收藏
页码:371e1 / 371e10
页数:10
相关论文
共 50 条
  • [31] Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer
    Tamada, Tsutomu
    Kido, Ayumu
    Takeuchi, Mitsuru
    Yamamoto, Akira
    Miyaji, Yoshiyuki
    Kanomata, Naoki
    Sone, Teruki
    EUROPEAN JOURNAL OF RADIOLOGY, 2019, 121
  • [32] Standardization of Multiparametric Prostate MR Imaging Using PI-RADS
    Bomers, Joyce G. R.
    Barentsz, Jelle O.
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [33] Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
    Gaudiano, Caterina
    Braccischi, Lorenzo
    Taninokuchi Tomassoni, Makoto
    Paccapelo, Alexandro
    Bianchi, Lorenzo
    Corcioni, Beniamino
    Ciccarese, Federica
    Schiavina, Riccardo
    Droghetti, Matteo
    Giunchi, Francesca
    Fiorentino, Michelangelo
    Brunocilla, Eugenio
    Golfieri, Rita
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] THE PROSTATE HEALTH INDEX IMPROVES PREDICTIVE VALUE IN PATIENTS WITH PI-RADS 3 LESIONS
    Pan, PanPoHsun
    Fan, Yu-Hua
    Lin, Tzu-Ping
    Chen, Wei-Ren
    Huang, Tzu-Hao
    Wei, Tzu-Chun
    Huang, I-Shen
    Lin, Chih-Chieh
    Huang, Eric Y. H.
    Chung, Hsiao-Jen
    Huang, William J. S.
    JOURNAL OF UROLOGY, 2020, 203 : E1101 - E1102
  • [35] The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI-RADS 3 lesions on multiparametric magnetic resonance imaging
    Kayar, Ridvan
    Tokuc, Emre
    Ozsoy, Emrah
    Demir, Samet
    Kayar, Kemal
    Topaktas, Ramazan
    Demir, Selamettin
    Ozturk, Metin
    PROSTATE, 2024, 84 (13): : 1244 - 1250
  • [36] Significance of atypical nodules upgraded to category 3 in PI-RADS version 2.1 for the prostate cancer diagnosis
    Asai, S.
    Kobayashi, M.
    Fukuda, S.
    Kimura, K.
    Fujiwara, M.
    Nakamura, Y.
    Ishikawa, Y.
    Waseda, Y.
    Tanaka, H.
    Yoshida, S.
    Yokoyama, M.
    Fujii, Y.
    EUROPEAN UROLOGY, 2023, 83
  • [37] Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?
    Patrick Asbach
    Anwar R. Padhani
    European Radiology, 2023, 33 : 5825 - 5827
  • [38] Clinical -Prostate cancer Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions
    Al Awamlh, Bashir Al Hussein
    Marks, Leonard S.
    Sonn, Geoffrey A.
    Natarajan, Shyam
    Fan, Richard E.
    Gross, Michael D.
    Mauer, Elizabeth
    Banerjee, Samprit
    Hectors, Stefanie
    Carlsson, Sigrid
    Margolis, Daniel J.
    Hu, Jim C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (07)
  • [39] PI-RADS 2.0 for Prostate MRI
    Franiel, T.
    Roethke, M.
    RADIOLOGE, 2017, 57 (08): : 665 - 678
  • [40] Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?
    Asbach, Patrick
    Padhani, Anwar R.
    EUROPEAN RADIOLOGY, 2023, 33 (08) : 5825 - 5827